Insight Molecular Diagnostics (IMDX) Payables (2015 - 2026)

Insight Molecular Diagnostics has reported Payables for 12 years, with the latest figure at $1.6 million in Q1 2026.

• Quarterly Payables fell 29.14% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 29.14% YoY) and the FY2025 annual result came in at $2.5 million, up 55.03% from the prior year.
• Payables declined to $1.6 million in Q1 2026 per IMDX's latest filing, from $2.5 million in the prior quarter.
• Over five years, Payables peaked at $2.6 million in Q1 2022 and troughed at $872000.0 in Q3 2024.
• A 5-year average of $1.5 million and a median of $1.3 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2023 and 2025: Payables plunged 64.5% in 2023, then soared 150.99% in 2025.
• Over 5 years, Payables stood at $1.3 million in 2022, then dropped by 23.94% to $953000.0 in 2023, then jumped by 72.19% to $1.6 million in 2024, then soared by 55.03% to $2.5 million in 2025, then sank by 36.52% to $1.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $1.6 million, $2.5 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.